Literature DB >> 11799337

Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia.

Thomas L Patterson1, Jonathan Lacro, Christine L McKibbin, Sherry Moscona, Troy Hughs, Dilip V Jeste.   

Abstract

Patients with schizophrenia who adhere to physicians' recommended use of medications are less likely to relapse than those who do not. Self-report measures of adherence have been criticized on a number of grounds. Here we describe a performance-based measure of medication management, the Medication Management Ability Assessment (MMAA), which represents a modification of the Medication Management Test used in individuals with HIV infection. Subjects were 104 patients older than 45 years with diagnoses of schizophrenia or schizoaffective disorder, and 33 normal comparison subjects (NCs). Subjects participated in a role-play task (MMAA) that simulated a prescribed medication regimen similar in complexity to one that an older person is likely to be exposed to. The total number of pills over that prescribed, total number of pills under that prescribed, and total number of correct responses were calculated. Self-report and prescription record data on adherence as well as data on measures of psychopathology, global cognitive status, and other clinical measures were also gathered. MMAA role-plays required 15 minutes, and its 1-week test-retest reliability was excellent (intraclass correlation coefficient, 0.96). Patients committed significantly more errors in medication management compared with NCs. Significantly more patients were classified as being nonadherent (i.e., taking +/-5%, 10%, 15%, or 20% of prescribed pills) compared with NCs. Patients with more severe cognitive deficits performed worse on the MMAA. MMAA performance was significantly related to prescription refill records, performance-based measures of everyday functioning, and self-reported quality of life. The MMAA is a useful instrument for observing ability to manage medications in patients with schizophrenia. The measure was related to severity of cognitive impairment, suggesting that adherence may improve with psychotropic and psychosocial interventions that target these deficits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799337     DOI: 10.1097/00004714-200202000-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  48 in total

1.  Medication Management Capacity and Its Neurocognitive Correlates in Huntington's Disease.

Authors:  Catherine A Sumida; Emily J Van Etten; Francesca V Lopez; David P Sheppard; Eva Pirogovsky-Turk; Jody Corey-Bloom; J Vincent Filoteo; Steven P Woods; Paul E Gilbert; Maureen Schmitter-Edgecombe
Journal:  Arch Clin Neuropsychol       Date:  2019-10-24       Impact factor: 2.813

Review 2.  Evidence-based strategies for the optimization of pharmacotherapy in older people.

Authors:  Eva Topinková; Jean Pierre Baeyens; Jean-Pierre Michel; Pierre-Olivier Lang
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

Review 3.  Measurement of functional capacity: a new approach to understanding functional differences and real-world behavioral adaptation in those with mental illness.

Authors:  Thomas L Patterson; Brent T Mausbach
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

4.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

5.  Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.

Authors:  Deepak C D'Souza; Rajiv Radhakrishnan; Edward Perry; Savita Bhakta; Nagendra M Singh; Richa Yadav; Danielle Abi-Saab; Brian Pittman; Santosh K Chaturvedi; Mahendra P Sharma; Morris Bell; Chittaranjan Andrade
Journal:  Neuropsychopharmacology       Date:  2012-10-24       Impact factor: 7.853

6.  Multicomponent analysis of a digital Trail Making Test.

Authors:  Robert P Fellows; Jessamyn Dahmen; Diane Cook; Maureen Schmitter-Edgecombe
Journal:  Clin Neuropsychol       Date:  2016-10-03       Impact factor: 3.535

7.  Direct measurement of disability.

Authors:  Philip D Harvey
Journal:  Psychiatry (Edgmont)       Date:  2009-10

8.  Evaluation of a Culturally Tailored Skills Intervention for Latinos with Persistent Psychotic Disorders.

Authors:  Brent T Mausbach; Jesus Bucardo; Veronica Cardenas; Christine L McKibbin; Concepcion Barrio; Sherrill R Goldman; Dilip V Jeste; Thomas L Patterson
Journal:  Am J Psychiatr Rehabil       Date:  2008-01-01

9.  Prospective memory deficits are associated with poorer everyday functioning in Parkinson's disease.

Authors:  Eva Pirogovsky; Steven Paul Woods; J Vincent Filoteo; Paul E Gilbert
Journal:  J Int Neuropsychol Soc       Date:  2012-07-30       Impact factor: 2.892

10.  Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia.

Authors:  Ashley S Roseman; John Kasckow; Ian Fellows; Katerine Osatuke; Thomas L Patterson; Somaia Mohamed; Sidney Zisook
Journal:  Int J Geriatr Psychiatry       Date:  2008-07       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.